SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021)

• Jaume Capdevila ^[6] ; Mª Auxiliadora Gómez ^[1] ; Mónica Guillot ^[2] ; David Páez ^[3] ; Carles Pericay ^[7] ; Maria José Safont ^[4] ; Noelia Tarazona ^[8] ; Ruth Vera ^[9] ; Joana Vidal ^[10] ; Javier Sastre ^[5]
  1. [1] Hospital Universitario Reina Sofia

     Hospital Universitario Reina Sofia

     Cordoba, España

     
  2. [2] Hospital Universitario Son Espases

     Hospital Universitario Son Espases

     Palma de Mallorca, España

     
  3. [3] Hospital de la Santa Creu i Sant Pau

     Hospital de la Santa Creu i Sant Pau

     Barcelona, España

     
  4. [4] Hospital General Universitario de Valencia

     Hospital General Universitario de Valencia

     Valencia, España

     
  5. [5] Hospital Clínico San Carlos de Madrid

     Hospital Clínico San Carlos de Madrid

     Madrid, España

     
  6. [6] Department of Medical Oncology, Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain
  7. [7] Department of Medical Oncology, Hospital Universitari Mútua de Terrassa, Terrassa, Spain
  8. [8] Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain Instituto de Salud Carlos III, CIBERONC, Madrid, Spain
  9. [9] Department of Medical Oncology, Hospital Universitario de Navarra; Navarrabiomed, IDISNA, Pamplona, Spain
  10. [10] Department of Medical Oncology, Hospital del Mar-IMIM, CIBERONC, Barcelona, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 4 (April), 2022, págs. 646-657
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Dialnet Métricas: 1 Cita
• Resumen

  • The management of localized rectal cancer requires a multidisciplinary approach to optimize outcomes, reduce morbidity and prevent under or overtreatments. While early stages may obtain benefit of local resections without any additional therapies, locally advanced rectal cancer becomes a challenge defining the better sequential strategy of surgery, radiotherapy and chemotherapy. The latest results of international phase III studies have positioned the total neoadjuvant therapy as a potential new standard of care in high risk rectal cancers, however, the best schedule is still not well defined.